Search clinical trials for: ACH-3102

Total 2929 results

Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Hepatitis C, Chronic

United States, Canada
Inovio Pharmaceuticals
University of Pennsylvania

Completed

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Cancer

United States
Inovio Pharmaceuticals

Completed

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Cervical Cancer

United States
Seoul National University Hospital
National Evidence-Based Healthcare Collaborating Agency; National Clinical... and other collaborators

Completed

Efficacy of Self-education Program for Advanced Care Planning(RCT) for General Population

Healthy

Korea, Republic of
Alios Biopharma Inc.
Alexion

Completed

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Chronic Hepatitis C

France
Azafaros A.G.

Active, not recruiting

Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease (RAINBOW)

Niemann-Pick Disease, Type C | GM2 Gangliosidosis

Brazil
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, New Zealand, Korea, Republic of, Italy
Alios Biopharma Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Chronic Hepatitis C

New Zealand, Moldova, Republic of, Mauritius, United Kingdom
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Healthy | Renal Dysfunction

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Hepatic Impairment

Hepatic Impairment

United States
Daewon Pharmaceutical Co., Ltd.

Unknown

A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients

Hypercholesterolemia
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Radiolabeled Danicopan in Healthy Male Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Multiple Doses of Danicopan in Healthy Participants

Healthy

New Zealand
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)

Diabetes Mellitus, Type 2
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

New Zealand, Korea, Republic of, Italy
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of a Single Dose of Danicopan in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Multiple Doses of ALXN2050 in Healthy Adults

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Single-dose ALXN2050 in Healthy Adults

Healthy

New Zealand
Merck Sharp & Dohme LLC

Completed

A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)

Type 2 Diabetes Mellitus | Chronic Renal Insufficiency
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and III

Netherlands, Australia, Belgium
Alexion Pharmaceuticals

Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease

United Kingdom, United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants

Healthy

New Zealand
Merck Sharp & Dohme LLC

Completed

Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Type 2 Diabetes (T2D)
Alexion

Completed

Study of ALXN2050 in Participants With Renal Impairment

Healthy | Renal Impairment

United States
Alexion

Recruiting

Study of ALXN2050 in Participants With Hepatic Impairment

Healthy | Impaired Hepatic Function

United States
Alexion Pharmaceuticals

Completed

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Healthy

United States
Alexion Pharmaceuticals

Completed

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Healthy

United States
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis | Myasthenia Gravis

United States, Spain, Korea, Republic of, Canada, Germany, Italy, Serbia, Taiwan
Syneos Health
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

Healthy Volunteers

Australia
Alexion Pharmaceuticals

Completed

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Healthy

United States
University of Zagreb
Croatian Institute of Health Insurance

Completed

Study of Autologous Conditioned Serum After Anterior Cruciate Ligament Reconstructive Surgery

Joint Instability

Croatia
Alexion

Active, not recruiting

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
Vidac Pharma
PharPoint Research, Inc.; Therapeutics, Inc.; Medistat Ltd., Israel

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis (Phase2b)

Actinic Keratosis

United States
NVP Healthcare

Completed

Evaluation of Pharmacokinetic and Safety of NVP-2102 and NVP-2102-R in Healthy Subjects

Healthy Subjects

Korea, Republic of
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Thailand, Korea, Republic of, United Kingdom, Israel, Czechia, Greece, Poland, Brazil, Japan, Canada, Malaysia
Hangzhou Endonom Medtech Co., Ltd.

Active, not recruiting

Guo's Aortic Arch Reconstruction: The First in Man Study of WeFlow-Arch Modular Embedded Branch Stent Graft System

Aortic Arch; Aneurysm, Dissecting

China
Alexion Pharmaceuticals
Parexel

Completed

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Healthy Adult Participants

United States
Alexion Pharmaceuticals

Completed

Study of Danicopan in Participants of Japanese Descent

Healthy

Australia
University of North Carolina, Chapel Hill
Womack Army Medical Center

Recruiting

Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury

Osteoarthritis, Knee | Post-traumatic Osteoarthritis | Anterior Cruciate Ligament Injuries | Quadriceps Muscle Atrophy

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Healthy

United Kingdom
Alexion Pharmaceuticals

Completed

A Study of the Effects of Food and Age on Danicopan

Healthy

United States
Zai Lab Pty. Ltd.

Unknown

Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects

Chronic Obstructive Pulmonary Disease | Asthma | Idiopathic Pulmonary Fibrosis

Australia
Alexion Pharmaceuticals, Inc.

Recruiting

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Lupus Nephritis | Immunoglobulin A Nephropathy | IgAN | LN

Australia, Spain, United Kingdom, China, Germany, Italy, Argentina, Peru, Korea, Republic of, Taiwan, Thailand, United States, Serbia, Israel, Brazil, Turkey, Mexico, Russian Federation
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

HCV Infection

United States, Germany, Netherlands
Addpharma Inc.

Completed

Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

Hypertension

Korea, Republic of
Zhejiang Cancer Hospital

Completed

The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery

Ovarian Neoplasm Epithelial
Vidac Pharma

Completed

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

Actinic Keratosis

United States
Mayo Clinic

Terminated

Effect of Advanced Care at Home vs. Traditional Brick-and-Mortar Hospital Care in Acutely Ill Adults: A Randomized Clinical Trial

The Trial Will Compare Two Care Delivery Models That Are Currently Being Used in Routine Practice Settings for Acute Hospitalization

United States
Mayo Clinic

Enrolling by invitation

Effect of Advanced Care at Home vs. Traditional Brick-and-Mortar Hospital Care in Acutely Ill Adults: A Pragmatic Clinical Trial

Acute Illness

United States
Alexion

Terminated

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

United States, Australia, Belgium, Italy, Netherlands

Search clinical trials for: ACH-3102

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations